{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:32:06Z","timestamp":1774686726141,"version":"3.50.1"},"reference-count":254,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,8,26]],"date-time":"2011-08-26T00:00:00Z","timestamp":1314316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Pediatr Endocrinol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1687-9856-2011-9","type":"journal-article","created":{"date-parts":[[2011,8,26]],"date-time":"2011-08-26T14:24:58Z","timestamp":1314368698000},"source":"Crossref","is-referenced-by-count":48,"title":["State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS)"],"prefix":"10.1186","volume":"2011","author":[{"name":"of the Drug and Therapeutics Committee of the Pediatric Endocrine Society","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H","family":"Geller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00e8le","family":"Pacaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhusmita","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,26]]},"reference":[{"issue":"7","key":"9_CR1","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1210\/jc.85.7.2434","volume":"85","author":"M Asuncion","year":"2000","unstructured":"Asuncion M, Calvo RM, San Millan JL: A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000, 85 (7): 2434-8. 10.1210\/jc.85.7.2434.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR2","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1210\/jc.2003-032046","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Woods KS, Reyna R: The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004, 89 (6): 2745-9. 10.1210\/jc.2003-032046.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.fertnstert.2005.03.051","volume":"84","author":"MO Goodarzi","year":"2005","unstructured":"Goodarzi MO, Quinones MJ, Azziz R: Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril. 2005, 84 (3): 766-9. 10.1016\/j.fertnstert.2005.03.051.","journal-title":"Fertil Steril"},{"issue":"1","key":"9_CR4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","volume":"81","author":"E Rotterdam","year":"2004","unstructured":"Rotterdam E: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility. 2004, 81 (1): 19-25.","journal-title":"Fertility and Sterility"},{"issue":"2","key":"9_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.fertnstert.2009.03.058","volume":"94","author":"BO Yildiz","year":"2010","unstructured":"Yildiz BO, Azziz R: Ovarian and adipose tissue dysfunction in polycystic ovary syndrome: report of the 4th special scientific meeting of the Androgen Excess and PCOS Society. Fertil Steril. 2010, 94 (2): 690-3. 10.1016\/j.fertnstert.2009.03.058.","journal-title":"Fertil Steril"},{"issue":"1","key":"9_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1046\/j.1365-2265.1997.2321049.x","volume":"47","author":"C Gilling-Smith","year":"1997","unstructured":"Gilling-Smith C, Story H, Rogers V: Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1997, 47 (1): 93-9. 10.1046\/j.1365-2265.1997.2321049.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"9_CR7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1210\/me.13.6.946","volume":"13","author":"VL Nelson","year":"1999","unstructured":"Nelson VL, Legro RS, Strauss JF: Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999, 13 (6): 946-57. 10.1210\/me.13.6.946.","journal-title":"Mol Endocrinol"},{"issue":"4","key":"9_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/humupd\/dmn015","volume":"14","author":"S Franks","year":"2008","unstructured":"Franks S, Stark J, Hardy K: Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008, 14 (4): 367-78. 10.1093\/humupd\/dmn015.","journal-title":"Hum Reprod Update"},{"issue":"6","key":"9_CR9","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.fertnstert.2008.12.138","volume":"93","author":"A Huang","year":"2010","unstructured":"Huang A, Brennan K, Azziz R: Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril. 2010, 93 (6): 1938-41. 10.1016\/j.fertnstert.2008.12.138.","journal-title":"Fertil Steril"},{"issue":"2","key":"9_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2265.1990.tb00857.x","volume":"32","author":"DS Kiddy","year":"1990","unstructured":"Kiddy DS, Sharp PS, White DM: Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf). 1990, 32 (2): 213-20. 10.1111\/j.1365-2265.1990.tb00857.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"9_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1210\/jc.2005-1329","volume":"91","author":"DA Ehrmann","year":"2006","unstructured":"Ehrmann DA, Liljenquist DR, Kasza K: Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006, 91 (1): 48-53. 10.1210\/jc.2005-1329.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.fertnstert.2004.01.041","volume":"82","author":"E Carmina","year":"2004","unstructured":"Carmina E, Lobo RA: Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004, 82 (3): 661-5. 10.1016\/j.fertnstert.2004.01.041.","journal-title":"Fertil Steril"},{"issue":"5","key":"9_CR13","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.fertnstert.2004.11.070","volume":"83","author":"CM DeUgarte","year":"2005","unstructured":"DeUgarte CM, Bartolucci AA, Azziz R: Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005, 83 (5): 1454-60. 10.1016\/j.fertnstert.2004.11.070.","journal-title":"Fertil Steril"},{"issue":"1","key":"9_CR14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1210\/jc.2007-1834","volume":"93","author":"BO Yildiz","year":"2008","unstructured":"Yildiz BO, Knochenhauer ES, Azziz R: Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2008, 93 (1): 162-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1210\/jc.2005-2153","volume":"91","author":"R Azziz","year":"2006","unstructured":"Azziz R: Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006, 91 (3): 781-5.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR16","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1210\/er.18.6.774","volume":"18","author":"A Dunaif","year":"1997","unstructured":"Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997, 18 (6): 774-800. 10.1210\/er.18.6.774.","journal-title":"Endocr Rev"},{"key":"9_CR17","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1210\/jc.2005-0628","volume":"90","author":"R Azziz","year":"2005","unstructured":"Azziz R, Marin C, Hoq L: Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005, 90: 4650-4658. 10.1210\/jc.2005-0628.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/jwh.2006.0098","volume":"16","author":"EO Talbott","year":"2007","unstructured":"Talbott EO, Zborowski JV, Rager JR: Polycystic ovarian syndrome (PCOS): a significant contributor to the overall burden of type 2 diabetes in women. J Womens Health (Larchmt). 2007, 16 (2): 191-7. 10.1089\/jwh.2006.0098.","journal-title":"J Womens Health (Larchmt)"},{"issue":"19","key":"9_CR19","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1001\/archinte.166.19.2081","volume":"166","author":"F Alvarez-Blasco","year":"2006","unstructured":"Alvarez-Blasco F, Botella-Carretero JI, San Millan JL: Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006, 166 (19): 2081-6. 10.1001\/archinte.166.19.2081.","journal-title":"Arch Intern Med"},{"issue":"1","key":"9_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2337\/diacare.22.1.141","volume":"22","author":"DA Ehrmann","year":"1999","unstructured":"Ehrmann DA, Barnes RB, Rosenfield RL: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999, 22 (1): 141-6. 10.2337\/diacare.22.1.141.","journal-title":"Diabetes Care"},{"issue":"1","key":"9_CR21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1210\/jc.2004-0229","volume":"90","author":"DA Ehrmann","year":"2005","unstructured":"Ehrmann DA, Kasza K, Azziz R: Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005, 90 (1): 66-71.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1210\/jc.84.1.165","volume":"84","author":"RS Legro","year":"1999","unstructured":"Legro RS, Kunselman AR, Dodson WC: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999, 84 (1): 165-9. 10.1210\/jc.84.1.165.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/humupd\/dmq001","volume":"16","author":"LJ Moran","year":"2010","unstructured":"Moran LJ, Misso ML, Wild RA: Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010, 16 (4): 347-63. 10.1093\/humupd\/dmq001.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"9_CR24","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1210\/jc.2009-2724","volume":"95","author":"RA Wild","year":"2010","unstructured":"Wild RA, Carmina E, Diamanti-Kandarakis E: Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010, 95 (5): 2038-49. 10.1210\/jc.2009-2724.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"9_CR25","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1210\/jc.2007-1549","volume":"92","author":"KE Salley","year":"2007","unstructured":"Salley KE, Wickham EP, Cheang KI: Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007, 92 (12): 4546-56. 10.1210\/jc.2007-1549.","journal-title":"J Clin Endocrinol Metab"},{"key":"9_CR26","first-page":"51","volume":"86","author":"EC Achard","year":"1921","unstructured":"Achard EC, Thiers J: Le virilisme pilaire et son association a l'insuffisance glycolitique (diab\u00e8te des femmes \u00e0 barbe). Bulletin Acad Nat Med, Paris. 1921, 86: 51-85.","journal-title":"Bulletin Acad Nat Med, Paris"},{"key":"9_CR27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9378(15)30642-6","volume":"29","author":"I Stein","year":"1935","unstructured":"Stein I, Leventhal M: Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935, 29: 181-91.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"9_CR28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0002-9378(83)90091-1","volume":"147","author":"RL Barbieri","year":"1983","unstructured":"Barbieri RL, Ryan KJ: Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol. 1983, 147 (1): 90-101.","journal-title":"Am J Obstet Gynecol"},{"issue":"14","key":"9_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJM197604012941401","volume":"294","author":"CR Kahn","year":"1976","unstructured":"Kahn CR, Flier JS, Bar RS: The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976, 294 (14): 739-45. 10.1056\/NEJM197604012941401.","journal-title":"N Engl J Med"},{"issue":"6","key":"9_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2337\/diabetes.40.6.777","volume":"40","author":"S O'Rahilly","year":"1991","unstructured":"O'Rahilly S, Choi WH, Patel P: Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms. Diabetes. 1991, 40 (6): 777-82. 10.2337\/diabetes.40.6.777.","journal-title":"Diabetes"},{"issue":"3","key":"9_CR31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1210\/edrv-13-3-566","volume":"13","author":"SI Taylor","year":"1992","unstructured":"Taylor SI, Cama A, Accili D: Mutations in the insulin receptor gene. Endocr Rev. 1992, 13 (3): 566-95.","journal-title":"Endocr Rev"},{"issue":"4209","key":"9_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.170678","volume":"190","author":"JS Flier","year":"1975","unstructured":"Flier JS, Kahn CR, Roth J: Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science. 1975, 190 (4209): 63-5. 10.1126\/science.170678.","journal-title":"Science"},{"issue":"2","key":"9_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2337\/diabetes.34.2.101","volume":"34","author":"JS Flier","year":"1985","unstructured":"Flier JS, Eastman RC, Minaker KL: Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes. Diabetes. 1985, 34 (2): 101-7. 10.2337\/diabetes.34.2.101.","journal-title":"Diabetes"},{"issue":"1","key":"9_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1210\/jcem-50-1-113","volume":"50","author":"GA Burghen","year":"1980","unstructured":"Burghen GA, Givens JR, Kitabchi AE: Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 1980, 50 (1): 113-6. 10.1210\/jcem-50-1-113.","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"9_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199509283331307","volume":"333","author":"S Franks","year":"1995","unstructured":"Franks S: Polycystic ovary syndrome. N Engl J Med. 1995, 333 (13): 853-61. 10.1056\/NEJM199509283331307.","journal-title":"N Engl J Med"},{"issue":"2","key":"9_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0950-351X(96)80085-1","volume":"10","author":"J Holte","year":"1996","unstructured":"Holte J: Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab. 1996, 10 (2): 221-47. 10.1016\/S0950-351X(96)80085-1.","journal-title":"Baillieres Clin Endocrinol Metab"},{"issue":"2","key":"9_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000049972","volume":"55","author":"S Toprak","year":"2001","unstructured":"Toprak S, Yonem A, Cakir B: Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res. 2001, 55 (2): 65-70. 10.1159\/000049972.","journal-title":"Horm Res"},{"issue":"5","key":"9_CR38","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/humrep\/deh207","volume":"19","author":"R Homburg","year":"2004","unstructured":"Homburg R, Lambalk CB: Polycystic ovary syndrome in adolescence--a therapeutic conundrum. Hum Reprod. 2004, 19 (5): 1039-42. 10.1093\/humrep\/deh207.","journal-title":"Hum Reprod"},{"issue":"1","key":"9_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0015-0282(99)00184-3","volume":"72","author":"P Acien","year":"1999","unstructured":"Acien P, Quereda F, Matallin P: Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril. 1999, 72 (1): 32-40. 10.1016\/S0015-0282(99)00184-3.","journal-title":"Fertil Steril"},{"issue":"2","key":"9_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0026-0495(99)90028-8","volume":"48","author":"M Ciampelli","year":"1999","unstructured":"Ciampelli M, Fulghesu AM, Cucinelli F: Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. 1999, 48 (2): 167-72. 10.1016\/S0026-0495(99)90028-8.","journal-title":"Metabolism"},{"issue":"9","key":"9_CR41","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2337\/diabetes.38.9.1165","volume":"38","author":"A Dunaif","year":"1989","unstructured":"Dunaif A, Segal KR, Futterweit W: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989, 38 (9): 1165-74. 10.2337\/diabetes.38.9.1165.","journal-title":"Diabetes"},{"issue":"2","key":"9_CR42","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1210\/jcem-57-2-356","volume":"57","author":"RJ Chang","year":"1983","unstructured":"Chang RJ, Nakamura RM, Judd HL: Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983, 57 (2): 356-9. 10.1210\/jcem-57-2-356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9_CR43","first-page":"545","volume":"66","author":"A Dunaif","year":"1985","unstructured":"Dunaif A, Hoffman AR, Scully RE: Clinical, biochemical, and ovarian morphologic features in women with acanthosis nigricans and masculinization. Obstet Gynecol. 1985, 66 (4): 545-52.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"9_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0015-0282(99)00468-9","volume":"73","author":"KJ Mather","year":"2000","unstructured":"Mather KJ, Kwan F, Corenblum B: Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril. 2000, 73 (1): 150-6. 10.1016\/S0015-0282(99)00468-9.","journal-title":"Fertil Steril"},{"issue":"1","key":"9_CR45","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1172\/JCI118064","volume":"96","author":"DA Ehrmann","year":"1995","unstructured":"Ehrmann DA, Sturis J, Byrne MM: Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995, 96 (1): 520-7. 10.1172\/JCI118064.","journal-title":"J Clin Invest"},{"issue":"3","key":"9_CR46","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1210\/jc.81.3.942","volume":"81","author":"A Dunaif","year":"1996","unstructured":"Dunaif A, Finegood DT: Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996, 81 (3): 942-7. 10.1210\/jc.81.3.942.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR47","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1210\/jc.2003-031378","volume":"89","author":"J Vrbikova","year":"2004","unstructured":"Vrbikova J, Cibula D, Dvorakova K: Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004, 89 (6): 2942-2945. 10.1210\/jc.2003-031378.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"9_CR48","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1210\/jc.81.8.2854","volume":"81","author":"AJ Morales","year":"1996","unstructured":"Morales AJ, Laughlin GA, Butzow T: Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 1996, 81 (8): 2854-64. 10.1210\/jc.81.8.2854.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR49","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1210\/jc.77.6.1636","volume":"77","author":"P Ovesen","year":"1993","unstructured":"Ovesen P, Moller J, Ingerslev HJ: Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1993, 77 (6): 1636-40. 10.1210\/jc.77.6.1636.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR50","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1210\/jc.2003-031205","volume":"89","author":"E Diamanti-Kandarakis","year":"2004","unstructured":"Diamanti-Kandarakis E, Kouli C, Alexandraki K: Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004, 89 (3): 1273-6. 10.1210\/jc.2003-031205.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR51","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1210\/jc.87.3.1017","volume":"87","author":"MR Palmert","year":"2002","unstructured":"Palmert MR, Gordon CM, Kartashov AI: Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002, 87 (3): 1017-23. 10.1210\/jc.87.3.1017.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1034\/j.1399-5448.2003.t01-1-00022.x","volume":"4","author":"WS Cutfield","year":"2003","unstructured":"Cutfield WS, Jefferies CA, Jackson WE: Evaluation of HOMA and QUICKI as measures of insulin sensitivity in prepubertal children. Pediatr Diabetes. 2003, 4 (3): 119-25. 10.1034\/j.1399-5448.2003.t01-1-00022.x.","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"9_CR53","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/humrep\/16.6.1255","volume":"16","author":"S Kirchengast","year":"2001","unstructured":"Kirchengast S, Huber J: Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod. 2001, 16 (6): 1255-60. 10.1093\/humrep\/16.6.1255.","journal-title":"Hum Reprod"},{"issue":"3","key":"9_CR54","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1046\/j.1365-2265.2003.01728.x","volume":"58","author":"L Ibanez","year":"2003","unstructured":"Ibanez L, Ong K, de Zegher F: Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinaemia and androgenaemia from prepuberty to postmenarche. Clin Endocrinol (Oxf). 2003, 58 (3): 372-9. 10.1046\/j.1365-2265.2003.01728.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"9_CR55","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1210\/jc.2003-030117","volume":"88","author":"L Ibanez","year":"2003","unstructured":"Ibanez L, De Zegher F: Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab. 2003, 88 (10): 4720-4. 10.1210\/jc.2003-030117.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"9_CR56","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.1210\/jc.2005-1002","volume":"90","author":"JJ Puder","year":"2005","unstructured":"Puder JJ, Varga S, Kraenzlin M: Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab. 2005, 90 (11): 6014-21. 10.1210\/jc.2005-1002.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR57","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/humrep\/15.6.1266","volume":"15","author":"LC Morin-Papunen","year":"2000","unstructured":"Morin-Papunen LC, Vauhkonen I, Koivunen RM: Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod. 2000, 15 (6): 1266-74. 10.1093\/humrep\/15.6.1266.","journal-title":"Hum Reprod"},{"issue":"6","key":"9_CR58","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1210\/jc.83.6.2001","volume":"83","author":"JE Nestler","year":"1998","unstructured":"Nestler JE, Jakubowicz DJ, Falcon de Vargas A: Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998, 83 (6): 2001-2005. 10.1210\/jc.83.6.2001.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/en.2003-0329","volume":"145","author":"I Munir","year":"2004","unstructured":"Munir I, Yen HW, Geller DH: Insulin augmentation of 17alpha-hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase-1\/2 in human ovarian theca cells. Endocrinology. 2004, 145 (1): 175-83.","journal-title":"Endocrinology"},{"issue":"9","key":"9_CR60","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJM199608293350902","volume":"335","author":"JE Nestler","year":"1996","unstructured":"Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996, 335 (9): 617-23. 10.1056\/NEJM199608293350902.","journal-title":"N Engl J Med"},{"issue":"12","key":"9_CR61","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1210\/jc.82.12.4075","volume":"82","author":"JE Nestler","year":"1997","unstructured":"Nestler JE, Jakubowicz DJ: Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab. 1997, 82 (12): 4075-9. 10.1210\/jc.82.12.4075.","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"9_CR62","doi-asserted-by":"publisher","first-page":"10619","DOI":"10.1073\/pnas.92.23.10619","volume":"92","author":"LH Zhang","year":"1995","unstructured":"Zhang LH, Rodriguez H, Ohno S: Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1995, 92 (23): 10619-23. 10.1073\/pnas.92.23.10619.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"9_CR63","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1210\/jcem-67-3-460","volume":"67","author":"SR Plymate","year":"1988","unstructured":"Plymate SR, Matej LA, Jones RE: Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988, 67 (3): 460-4. 10.1210\/jcem-67-3-460.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR64","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1210\/jcem-72-1-83","volume":"72","author":"JE Nestler","year":"1991","unstructured":"Nestler JE, Powers LP, Matt DW: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1991, 72 (1): 83-9. 10.1210\/jcem-72-1-83.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9_CR65","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/humupd\/dml017","volume":"12","author":"SK Blank","year":"2006","unstructured":"Blank SK, McCartney CR, Marshall JC: The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update. 2006, 12 (4): 351-61. 10.1093\/humupd\/dml017.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"9_CR66","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1210\/jc.2004-2359","volume":"90","author":"S Chhabra","year":"2005","unstructured":"Chhabra S, McCartney CR, Yoo RY: Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. J Clin Endocrinol Metab. 2005, 90 (5): 2810-5. 10.1210\/jc.2004-2359.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9_CR67","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0889-8529(05)70071-2","volume":"28","author":"JC Marshall","year":"1999","unstructured":"Marshall JC, Eagleson CA: Neuroendocrine aspects of polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999, 28 (2): 295-324. 10.1016\/S0889-8529(05)70071-2.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"9_CR68","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1210\/jc.2004-1040","volume":"90","author":"RV Mehta","year":"2005","unstructured":"Mehta RV, Patel KS, Coffler MS: Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment. J Clin Endocrinol Metab. 2005, 90 (4): 2136-41. 10.1210\/jc.2004-1040.","journal-title":"J Clin Endocrinol Metab"},{"key":"9_CR69","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1210\/jc.2005-2099","volume":"91","author":"YLea Pagan","year":"2006","unstructured":"Pagan YLea: Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metab. 2006, 91: 1309-16. 10.1210\/jc.2005-2099.","journal-title":"J Clin Endocrinol Metab"},{"key":"9_CR70","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1210\/jc.2006-2716","volume":"92","author":"SSea Srouji","year":"2007","unstructured":"Srouji SSea: Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. J Clin Endocrinol Metab. 2007, 92: 1347-52. 10.1210\/jc.2006-2716.","journal-title":"J Clin Endocrinol Metab"},{"key":"9_CR71","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/BF03350785","volume":"21","author":"JE Hall","year":"1998","unstructured":"Hall JE, Taylor AE, Hayes RJ: Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome. J Endocrinol Invest. 1998, 21: 602-11.","journal-title":"J Endocrinol Invest"},{"key":"9_CR72","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1210\/jc.82.7.2248","volume":"82","author":"AEea Taylor","year":"1997","unstructured":"Taylor AEea: Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997, 82: 2248-56. 10.1210\/jc.82.7.2248.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR73","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1210\/jc.2005-1494","volume":"91","author":"JM Vink","year":"2006","unstructured":"Vink JM, Sadrzadeh S, Lambalk CB: Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006, 91 (6): 2100-4. 10.1210\/jc.2005-1494.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR74","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-2007-992919","volume":"26","author":"MO Goodarzi","year":"2008","unstructured":"Goodarzi MO: Looking for polycystic ovary syndrome genes: rational and best strategy. Semin Reprod Med. 2008, 26 (1): 5-13. 10.1055\/s-2007-992919.","journal-title":"Semin Reprod Med"},{"issue":"5","key":"9_CR75","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1210\/jc.2003-031640","volume":"89","author":"M Gaasenbeek","year":"2004","unstructured":"Gaasenbeek M, Powell BL, Sovio U: Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab. 2004, 89 (5): 2408-13. 10.1210\/jc.2003-031640.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR76","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1210\/jc.2007-1712","volume":"93","author":"MO Goodarzi","year":"2008","unstructured":"Goodarzi MO, Jones MR, Antoine HJ: Nonreplication of the type 5 17beta-hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008, 93 (1): 300-3.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9_CR77","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1210\/jc.2004-2485","volume":"90","author":"BL Powell","year":"2005","unstructured":"Powell BL, Haddad L, Bennett A: Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J Clin Endocrinol Metab. 2005, 90 (5): 2988-93. 10.1210\/jc.2004-2485.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"9_CR78","doi-asserted-by":"publisher","first-page":"6623","DOI":"10.1210\/jc.2005-0622","volume":"90","author":"M Urbanek","year":"2005","unstructured":"Urbanek M, Woodroffe A, Ewens KG: Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab. 2005, 90 (12): 6623-9. 10.1210\/jc.2005-0622.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"9_CR79","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1210\/jc.2009-0931","volume":"94","author":"MR Jones","year":"2009","unstructured":"Jones MR, Mathur R, Cui J: Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17beta-hydroxysteroid dehydrogenase gene. J Clin Endocrinol Metab. 2009, 94 (12): 5034-8. 10.1210\/jc.2009-0931.","journal-title":"J Clin Endocrinol Metab"},{"key":"9_CR80","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1210\/jc.2009-2703","volume":"95","author":"KGea Ewens","year":"2010","unstructured":"Ewens KGea: Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab. 2010, 95: 2306-15. 10.1210\/jc.2009-2703.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR81","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1210\/jc.84.1.38","volume":"84","author":"A Govind","year":"1999","unstructured":"Govind A, Obhrai MS, Clayton RN: Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab. 1999, 84 (1): 38-43. 10.1210\/jc.84.1.38.","journal-title":"J Clin Endocrinol Metab"},{"issue":"25","key":"9_CR82","doi-asserted-by":"publisher","first-page":"14956","DOI":"10.1073\/pnas.95.25.14956","volume":"95","author":"RS Legro","year":"1998","unstructured":"Legro RS, Driscoll D, Strauss JF: Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998, 95 (25): 14956-60. 10.1073\/pnas.95.25.14956.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"9_CR83","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000293493","volume":"28","author":"O Lunde","year":"1989","unstructured":"Lunde O, Magnus P, Sandvik L: Familial clustering in the polycystic ovarian syndrome. Gynecol Obstet Invest. 1989, 28 (1): 23-30. 10.1159\/000293493.","journal-title":"Gynecol Obstet Invest"},{"issue":"1","key":"9_CR84","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0015-0282(00)01662-9","volume":"75","author":"MD Kahsar-Miller","year":"2001","unstructured":"Kahsar-Miller MD, Nixon C, Boots LR: Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001, 75 (1): 53-8. 10.1016\/S0015-0282(00)01662-9.","journal-title":"Fertil Steril"},{"issue":"7","key":"9_CR85","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00125-002-0836-3","volume":"45","author":"T Sir-Petermann","year":"2002","unstructured":"Sir-Petermann T, Angel B, Maliqueo M: Prevalence of Type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia. 2002, 45 (7): 959-64. 10.1007\/s00125-002-0836-3.","journal-title":"Diabetologia"},{"issue":"18","key":"9_CR86","doi-asserted-by":"publisher","first-page":"7030","DOI":"10.1073\/pnas.0602025103","volume":"103","author":"S Sam","year":"2006","unstructured":"Sam S, Legro RS, Essah PA: Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A. 2006, 103 (18): 7030-5. 10.1073\/pnas.0602025103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"9_CR87","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1210\/jc.2004-2217","volume":"90","author":"S Sam","year":"2005","unstructured":"Sam S, Legro RS, Bentley-Lewis R: Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005, 90 (8): 4797-802. 10.1210\/jc.2004-2217.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9_CR88","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1210\/jc.86.5.2027","volume":"86","author":"S Colilla","year":"2001","unstructured":"Colilla S, Cox NJ, Ehrmann DA: Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab. 2001, 86 (5): 2027-31. 10.1210\/jc.86.5.2027.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9_CR89","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1210\/jc.87.5.2134","volume":"87","author":"RS Legro","year":"2002","unstructured":"Legro RS, Kunselman AR, Demers L: Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002, 87 (5): 2134-8. 10.1210\/jc.87.5.2134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR90","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1365-2265.2004.01981.x","volume":"60","author":"R Kaushal","year":"2004","unstructured":"Kaushal R, Parchure N, Bano G: Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries. Clin Endocrinol (Oxf). 2004, 60 (3): 322-8. 10.1111\/j.1365-2265.2004.01981.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"9_CR91","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1210\/jc.2009-1333","volume":"94","author":"AD Coviello","year":"2009","unstructured":"Coviello AD, Sam S, Legro RS: High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity. J Clin Endocrinol Metab. 2009, 94 (11): 4361-6. 10.1210\/jc.2009-1333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR92","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1210\/jc.2008-2836","volume":"94","author":"T Sir-Petermann","year":"2009","unstructured":"Sir-Petermann T, Codner E, Perez V: Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009, 94 (6): 1923-30. 10.1210\/jc.2008-2836.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"9_CR93","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1210\/jc.2007-1036","volume":"92","author":"T Sir-Petermann","year":"2007","unstructured":"Sir-Petermann T, Maliqueo M, Codner E: Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007, 92 (12): 4637-42. 10.1210\/jc.2007-1036.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9_CR94","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1210\/jc.2007-1958","volume":"93","author":"SC Kent","year":"2008","unstructured":"Kent SC, Gnatuk CL, Kunselman AR: Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2008, 93 (5): 1662-9. 10.1210\/jc.2007-1958.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR95","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/0197-0070(90)90106-C","volume":"11","author":"GL Francis","year":"1990","unstructured":"Francis GL, Getts A, McPherson JC: Preliminary results suggesting exaggerated ovarian androgen production early in the course of polycystic ovary syndrome. J Adolesc Health Care. 1990, 11 (6): 480-4. 10.1016\/0197-0070(90)90106-C.","journal-title":"J Adolesc Health Care"},{"issue":"2","key":"9_CR96","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jc.2005-1666","volume":"91","author":"AD Coviello","year":"2006","unstructured":"Coviello AD, Legro RS, Dunaif A: Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006, 91 (2): 492-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9_CR97","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1210\/jc.2005-2665","volume":"91","author":"JC Marshall","year":"2006","unstructured":"Marshall JC: Obesity in adolescent girls: is excess androgen the real bad actor?. J Clin Endocrinol Metab. 2006, 91 (2): 393-5. 10.1210\/jc.2005-2665.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR98","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1067\/mpd.2001.109603","volume":"138","author":"VD Lewy","year":"2001","unstructured":"Lewy VD, Danadian K, Witchel SF: Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2001, 138 (1): 38-44. 10.1067\/mpd.2001.109603.","journal-title":"J Pediatr"},{"issue":"10","key":"9_CR99","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1210\/jc.80.10.2966","volume":"80","author":"D Apter","year":"1995","unstructured":"Apter D, Butzow T, Laughlin GA: Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab. 1995, 80 (10): 2966-73. 10.1210\/jc.80.10.2966.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"9_CR100","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1210\/jc.2003-030617","volume":"88","author":"ME Silfen","year":"2003","unstructured":"Silfen ME, Denburg MR, Manibo AM: Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab. 2003, 88 (10): 4682-8. 10.1210\/jc.2003-030617.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR101","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1210\/jc.81.3.1237","volume":"81","author":"L Ibanez","year":"1996","unstructured":"Ibanez L, Potau N, Zampolli M: Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1996, 81 (3): 1237-43. 10.1210\/jc.81.3.1237.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"9_CR102","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1210\/jc.82.7.2283","volume":"82","author":"L Ibanez","year":"1997","unstructured":"Ibanez L, Potau N, Zampolli M: Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab. 1997, 82 (7): 2283-8. 10.1210\/jc.82.7.2283.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9_CR103","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2265.1999.00778.x","volume":"51","author":"L Ibanez","year":"1999","unstructured":"Ibanez L, Castell C, Tresserras R: Increased prevalence of type 2 diabetes mellitus and impaired glucose tolerance in first-degree relatives of girls with a history of precocious pubarche. Clin Endocrinol (Oxf). 1999, 51 (4): 395-401. 10.1046\/j.1365-2265.1999.00778.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"9_CR104","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/jc.84.8.2691","volume":"84","author":"L Ibanez","year":"1999","unstructured":"Ibanez L, de Zegher F, Potau N: Anovulation after precocious pubarche: early markers and time course in adolescence. J Clin Endocrinol Metab. 1999, 84 (8): 2691-5. 10.1210\/jc.84.8.2691.","journal-title":"J Clin Endocrinol Metab"},{"issue":"433","key":"9_CR105","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1651-2227.1999.tb14407.x","volume":"88","author":"L Ibanez","year":"1999","unstructured":"Ibanez L, Potau N, De Zegher F: Endocrinology and metabolism after premature pubarche in girls. Acta Paediatr Suppl. 1999, 88 (433): 73-7. 10.1111\/j.1651-2227.1999.tb14407.x.","journal-title":"Acta Paediatr Suppl"},{"issue":"2","key":"9_CR106","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1210\/jc.80.2.614","volume":"80","author":"E Oppenheimer","year":"1995","unstructured":"Oppenheimer E, Linder B, DiMartino-Nardi J: Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans. J Clin Endocrinol Metab. 1995, 80 (2): 614-8. 10.1210\/jc.80.2.614.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR107","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0022-3476(85)80182-7","volume":"107","author":"GE Richards","year":"1985","unstructured":"Richards GE, Cavallo A, Meyer WJ: Obesity, acanthosis nigricans, insulin resistance, and hyperandrogenemia: pediatric perspective and natural history. J Pediatr. 1985, 107 (6): 893-7. 10.1016\/S0022-3476(85)80182-7.","journal-title":"J Pediatr"},{"issue":"5","key":"9_CR108","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1210\/jc.2005-1852","volume":"91","author":"CR McCartney","year":"2006","unstructured":"McCartney CR, Prendergast KA, Chhabra S: The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab. 2006, 91 (5): 1714-22. 10.1210\/jc.2005-1852.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR109","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1210\/jc.2006-2012","volume":"92","author":"RL Rosenfield","year":"2007","unstructured":"Rosenfield RL: Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007, 92 (3): 787-96.","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"9_CR110","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJM198311173092002","volume":"309","author":"B Zumoff","year":"1983","unstructured":"Zumoff B, Freeman R, Coupey S: A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome. N Engl J Med. 1983, 309 (20): 1206-9. 10.1056\/NEJM198311173092002.","journal-title":"N Engl J Med"},{"issue":"2","key":"9_CR111","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1530\/acta.0.1260132","volume":"126","author":"PO Dale","year":"1992","unstructured":"Dale PO, Tanbo T, Djoseland O: Persistence of hyperinsulinemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist. Acta Endocrinol (Copenh). 1992, 126 (2): 132-6.","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"3","key":"9_CR112","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1210\/jcem-70-3-699","volume":"70","author":"A Dunaif","year":"1990","unstructured":"Dunaif A, Green G, Futterweit W: Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1990, 70 (3): 699-704. 10.1210\/jcem-70-3-699.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR113","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0015-0282(16)49211-3","volume":"45","author":"ME Geffner","year":"1986","unstructured":"Geffner ME, Kaplan SA, Bersch N: Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril. 1986, 45 (3): 327-33.","journal-title":"Fertil Steril"},{"issue":"6","key":"9_CR114","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1530\/eje.0.1330718","volume":"133","author":"A Lasco","year":"1995","unstructured":"Lasco A, Cucinotta D, Gigante A: No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide. Eur J Endocrinol. 1995, 133 (6): 718-22. 10.1530\/eje.0.1330718.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"9_CR115","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0026-0495(95)90062-4","volume":"44","author":"E Diamanti-Kandarakis","year":"1995","unstructured":"Diamanti-Kandarakis E, Mitrakou A, Hennes MM: Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism. 1995, 44 (4): 525-31. 10.1016\/0026-0495(95)90062-4.","journal-title":"Metabolism"},{"issue":"8","key":"9_CR116","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1210\/jc.83.8.2699","volume":"83","author":"E Diamanti-Kandarakis","year":"1998","unstructured":"Diamanti-Kandarakis E, Mitrakou A, Raptis S: The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1998, 83 (8): 2699-705. 10.1210\/jc.83.8.2699.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR117","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/09513590400004736","volume":"19","author":"I Sahin","year":"2004","unstructured":"Sahin I, Serter R, Karakurt F: Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. Gynecol Endocrinol. 2004, 19 (3): 115-24. 10.1080\/09513590400004736.","journal-title":"Gynecol Endocrinol"},{"issue":"9","key":"9_CR118","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF03350786","volume":"21","author":"D Apter","year":"1998","unstructured":"Apter D: How possible is the prevention of polycystic ovary syndrome development in adolescent patients with early onset of hyperandrogenism. J Endocrinol Invest. 1998, 21 (9): 613-7.","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"9_CR119","doi-asserted-by":"crossref","first-page":"356 e1","DOI":"10.1016\/j.amjmed.2005.10.059","volume":"119","author":"E Carmina","year":"2006","unstructured":"Carmina E, Orio F, Palomba S: Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med. 2006, 119 (4): 356 e1-6.","journal-title":"Am J Med"},{"issue":"2","key":"9_CR120","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2004.04.007","volume":"175","author":"K Lakhani","year":"2004","unstructured":"Lakhani K, Hardiman P, Seifalian AM: Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis. 2004, 175 (2): 353-9. 10.1016\/j.atherosclerosis.2004.04.007.","journal-title":"Atherosclerosis"},{"issue":"5","key":"9_CR121","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1210\/jc.2004-2363","volume":"90","author":"A Vryonidou","year":"2005","unstructured":"Vryonidou A, Papatheodorou A, Tavridou A: Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005, 90 (5): 2740-6. 10.1210\/jc.2004-2363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9_CR122","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0015-0282(03)00734-9","volume":"80","author":"MO Goodarzi","year":"2003","unstructured":"Goodarzi MO, Korenman SG: The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril. 2003, 80 (2): 255-8. 10.1016\/S0015-0282(03)00734-9.","journal-title":"Fertil Steril"},{"issue":"5","key":"9_CR123","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/153537020422900504","volume":"229","author":"DJ Salmi","year":"2004","unstructured":"Salmi DJ, Zisser HC, Jovanovic L: Screening for and treatment of polycystic ovary syndrome in teenagers. Exp Biol Med (Maywood). 2004, 229 (5): 369-77.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"9_CR124","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.fertnstert.2004.02.104","volume":"82","author":"KM Hoeger","year":"2004","unstructured":"Hoeger KM, Kochman L, Wixom N: A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and\/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril. 2004, 82 (2): 421-9. 10.1016\/j.fertnstert.2004.02.104.","journal-title":"Fertil Steril"},{"issue":"4","key":"9_CR125","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1210\/jc.84.4.1470","volume":"84","author":"MM Huber-Buchholz","year":"1999","unstructured":"Huber-Buchholz MM, Carey DG, Norman RJ: Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999, 84 (4): 1470-4. 10.1210\/jc.84.4.1470.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR126","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2265.1992.tb02909.x","volume":"36","author":"DS Kiddy","year":"1992","unstructured":"Kiddy DS, Hamilton-Fairley D, Bush A: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992, 36 (1): 105-11. 10.1111\/j.1365-2265.1992.tb02909.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"9_CR127","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/GRF.0b013e31802f54c8","volume":"50","author":"KM Hoeger","year":"2007","unstructured":"Hoeger KM: Obesity and lifestyle management in polycystic ovary syndrome. Clin Obstet Gynecol. 2007, 50 (1): 277-94. 10.1097\/GRF.0b013e31802f54c8.","journal-title":"Clin Obstet Gynecol"},{"issue":"3","key":"9_CR128","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/humrep\/dem391","volume":"23","author":"S Palomba","year":"2008","unstructured":"Palomba S, Giallauria F, Falbo A: Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod. 2008, 23 (3): 642-50. 10.1093\/humrep\/dem391.","journal-title":"Hum Reprod"},{"issue":"2","key":"9_CR129","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"91","author":"R Azziz","year":"2009","unstructured":"Azziz R, Carmina E, Dewailly D: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009, 91 (2): 456-88. 10.1016\/j.fertnstert.2008.06.035.","journal-title":"Fertil Steril"},{"issue":"7","key":"9_CR130","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1210\/jc.2006-2725","volume":"92","author":"E Carmina","year":"2007","unstructured":"Carmina E, Bucchieri S, Esposito A: Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007, 92 (7): 2500-5. 10.1210\/jc.2006-2725.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"9_CR131","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1210\/jc.80.12.3469","volume":"80","author":"M Wabitsch","year":"1995","unstructured":"Wabitsch M, Hauner H, Heinze E: Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J Clin Endocrinol Metab. 1995, 80 (12): 3469-75. 10.1210\/jc.80.12.3469.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"9_CR132","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1210\/jc.2005-0438","volume":"90","author":"T Reinehr","year":"2005","unstructured":"Reinehr T, de Sousa G, Roth CL: Androgens before and after weight loss in obese children. J Clin Endocrinol Metab. 2005, 90 (10): 5588-95. 10.1210\/jc.2005-0438.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"9_CR133","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1210\/jc.2008-0461","volume":"93","author":"K Hoeger","year":"2008","unstructured":"Hoeger K, Davidson K, Kochman L: The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008, 93 (11): 4299-306. 10.1210\/jc.2008-0461.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR134","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/09513590903215581","volume":"26","author":"CF Otta","year":"2010","unstructured":"Otta CF, Wior M, Iraci GS: Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. Gynecol Endocrinol. 2010, 26 (3): 173-8. 10.3109\/09513590903215581.","journal-title":"Gynecol Endocrinol"},{"issue":"8","key":"9_CR135","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1210\/jc.85.8.2767","volume":"85","author":"R Pasquali","year":"2000","unstructured":"Pasquali R, Gambineri A, Biscotti D: Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 2000, 85 (8): 2767-74. 10.1210\/jc.85.8.2767.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9_CR136","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.soard.2005.02.008","volume":"1","author":"GM Eid","year":"2005","unstructured":"Eid GM, Cottam DR, Velcu LM: Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2005, 1 (2): 77-80. 10.1016\/j.soard.2005.02.008.","journal-title":"Surg Obes Relat Dis"},{"issue":"12","key":"9_CR137","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1210\/jc.2005-1490","volume":"90","author":"HF Escobar-Morreale","year":"2005","unstructured":"Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F: The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2005, 90 (12): 6364-9. 10.1210\/jc.2005-1490.","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"9_CR138","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1517\/14656560802559932","volume":"9","author":"HF Escobar-Morreale","year":"2008","unstructured":"Escobar-Morreale HF: Polycystic ovary syndrome: treatment strategies and management. Expert Opin Pharmacother. 2008, 9 (17): 2995-3008. 10.1517\/14656560802559932.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"9_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jamcollsurg.2007.07.028","volume":"206","author":"PL Schilling","year":"2008","unstructured":"Schilling PL, Davis MM, Albanese CT: National trends in adolescent bariatric surgical procedures and implications for surgical centers of excellence. J Am Coll Surg. 2008, 206 (1): 1-12. 10.1016\/j.jamcollsurg.2007.07.028.","journal-title":"J Am Coll Surg"},{"issue":"4","key":"9_CR140","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1210\/jc.2007-2437","volume":"93","author":"KA Martin","year":"2008","unstructured":"Martin KA, Chang RJ, Ehrmann DA: Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008, 93 (4): 1105-20. 10.1210\/jc.2007-2437.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9_CR141","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/humrep\/del407","volume":"22","author":"S Nader","year":"2007","unstructured":"Nader S, Diamanti-Kandarakis E: Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod. 2007, 22 (2): 317-22.","journal-title":"Hum Reprod"},{"issue":"12","key":"9_CR142","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1056\/NEJMra041536","volume":"352","author":"DA Ehrmann","year":"2005","unstructured":"Ehrmann DA: Polycystic ovary syndrome. N Engl J Med. 2005, 352 (12): 1223-36. 10.1056\/NEJMra041536.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"9_CR143","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.maturitas.2003.09.016","volume":"46","author":"AE Schindler","year":"2003","unstructured":"Schindler AE: Differential effects of progestins on hemostasis. Maturitas. 2003, 46 (Suppl 1): S31-7.","journal-title":"Maturitas"},{"issue":"1","key":"9_CR144","first-page":"103","volume":"78","author":"DL Cassidenti","year":"1991","unstructured":"Cassidenti DL, Paulson RJ, Serafini P: Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstet Gynecol. 1991, 78 (1): 103-7.","journal-title":"Obstet Gynecol"},{"issue":"2 Suppl","key":"9_CR145","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1067\/mob.2001.117415","volume":"185","author":"GL Hammond","year":"2001","unstructured":"Hammond GL, Rabe T, Wagner JD: Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy. Am J Obstet Gynecol. 2001, 185 (2 Suppl): S24-31.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"9_CR146","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/humrep\/dem379","volume":"23","author":"S Franks","year":"2008","unstructured":"Franks S, Layton A, Glasier A: Cyproterone acetate\/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Hum Reprod. 2008, 23 (2): 231-2.","journal-title":"Hum Reprod"},{"issue":"5","key":"9_CR147","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1210\/jcem-38-5-727","volume":"38","author":"JR Givens","year":"1974","unstructured":"Givens JR, Andersen RN, Wiser WL: Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive. J Clin Endocrinol Metab. 1974, 38 (5): 727-35. 10.1210\/jcem-38-5-727.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9_CR148","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0010-7824(90)90034-S","volume":"41","author":"N van der Vange","year":"1990","unstructured":"van der Vange N, Blankenstein MA, Kloosterboer HJ: Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception. 1990, 41 (4): 345-52. 10.1016\/0010-7824(90)90034-S.","journal-title":"Contraception"},{"issue":"3","key":"9_CR149","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.contraception.2010.04.002","volume":"82","author":"V De Leo","year":"2010","unstructured":"De Leo V, Di Sabatino A, Musacchio MC: Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception. 2010, 82 (3): 276-80. 10.1016\/j.contraception.2010.04.002.","journal-title":"Contraception"},{"issue":"5","key":"9_CR150","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0015-0282(02)02993-X","volume":"77","author":"G Mastorakos","year":"2002","unstructured":"Mastorakos G, Koliopoulos C, Creatsas G: Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril. 2002, 77 (5): 919-27. 10.1016\/S0015-0282(02)02993-X.","journal-title":"Fertil Steril"},{"issue":"12","key":"9_CR151","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1210\/jc.80.12.3412","volume":"80","author":"JS Heiner","year":"1995","unstructured":"Heiner JS, Greendale GA, Kawakami AK: Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. J Clin Endocrinol Metab. 1995, 80 (12): 3412-8. 10.1210\/jc.80.12.3412.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR152","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1083-3188(02)00205-X","volume":"16","author":"ME Trent","year":"2003","unstructured":"Trent ME, Rich M, Austin SB: Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. J Pediatr Adolesc Gynecol. 2003, 16 (1): 33-7. 10.1016\/S1083-3188(02)00205-X.","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"2","key":"9_CR153","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0028-2243(91)90092-Y","volume":"41","author":"E Dahlgren","year":"1991","unstructured":"Dahlgren E, Friberg LG, Johansson S: Endometrial carcinoma; ovarian dysfunction--a risk factor in young women. Eur J Obstet Gynecol Reprod Biol. 1991, 41 (2): 143-50. 10.1016\/0028-2243(91)90092-Y.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"9_CR154","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ejogrb.2006.01.023","volume":"127","author":"G Iatrakis","year":"2006","unstructured":"Iatrakis G, Tsionis C, Adonakis G: Polycystic ovarian syndrome, insulin resistance and thickness of the endometrium. Eur J Obstet Gynecol Reprod Biol. 2006, 127 (2): 218-21. 10.1016\/j.ejogrb.2006.01.023.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"9_CR155","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/humrep\/dei420","volume":"21","author":"OC Pillay","year":"2006","unstructured":"Pillay OC, Te Fong LF, Crow JC: The association between polycystic ovaries and endometrial cancer. Hum Reprod. 2006, 21 (4): 924-9.","journal-title":"Hum Reprod"},{"issue":"3","key":"9_CR156","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/01.AOG.0000255664.48970.e6","volume":"109","author":"G Lurie","year":"2007","unstructured":"Lurie G, Thompson P, McDuffie KE: Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol. 2007, 109 (3): 597-607. 10.1097\/01.AOG.0000255664.48970.e6.","journal-title":"Obstet Gynecol"},{"issue":"1 Pt 1","key":"9_CR157","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0002-9378(95)90125-6","volume":"172","author":"DA Grimes","year":"1995","unstructured":"Grimes DA, Economy KE: Primary prevention of gynecologic cancers. Am J Obstet Gynecol. 1995, 172 (1 Pt 1): 227-35.","journal-title":"Am J Obstet Gynecol"},{"key":"9_CR158","doi-asserted-by":"crossref","unstructured":"Costello M, Shrestha B, Eden J: Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007, CD005552-1","DOI":"10.1002\/14651858.CD005552.pub2"},{"issue":"2","key":"9_CR159","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.fertnstert.2005.07.1306","volume":"85","author":"G Mastorakos","year":"2006","unstructured":"Mastorakos G, Koliopoulos C, Deligeoroglou E: Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril. 2006, 85 (2): 420-7. 10.1016\/j.fertnstert.2005.07.1306.","journal-title":"Fertil Steril"},{"issue":"7","key":"9_CR160","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1210\/jc.2004-1958","volume":"90","author":"JP Baillargeon","year":"2005","unstructured":"Baillargeon JP, McClish DK, Essah PA: Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab. 2005, 90 (7): 3863-70. 10.1210\/jc.2004-1958.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR161","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0010-7824(03)00073-8","volume":"68","author":"YS Khader","year":"2003","unstructured":"Khader YS, Rice J, John L: Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception. 2003, 68 (1): 11-7. 10.1016\/S0010-7824(03)00073-8.","journal-title":"Contraception"},{"issue":"2","key":"9_CR162","first-page":"107","volume":"55","author":"RT Burkman","year":"2003","unstructured":"Burkman RT: Hormone replacement therapy. Current controversies. Minerva Ginecol. 2003, 55 (2): 107-16.","journal-title":"Minerva Ginecol"},{"issue":"6","key":"9_CR163","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/07853890310001267","volume":"35","author":"D Keeling","year":"2003","unstructured":"Keeling D: Combined oral contraceptives and the risk of myocardial infarction. Ann Med. 2003, 35 (6): 413-8. 10.1080\/07853890310001267.","journal-title":"Ann Med"},{"issue":"7","key":"9_CR164","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1210\/jc.2008-0752","volume":"93","author":"RL Barbieri","year":"2008","unstructured":"Barbieri RL: Update in female reproduction: a life-cycle approach. J Clin Endocrinol Metab. 2008, 93 (7): 2439-46. 10.1210\/jc.2008-0752.","journal-title":"J Clin Endocrinol Metab"},{"issue":"28","key":"9_CR165","doi-asserted-by":"publisher","first-page":"25226","DOI":"10.1074\/jbc.M202489200","volume":"277","author":"LG Fryer","year":"2002","unstructured":"Fryer LG, Parbu-Patel A, Carling D: The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002, 277 (28): 25226-32. 10.1074\/jbc.M202489200.","journal-title":"J Biol Chem"},{"issue":"4","key":"9_CR166","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/humupd\/dmi015","volume":"11","author":"MA Checa","year":"2005","unstructured":"Checa MA, Requena A, Salvador C: Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update. 2005, 11 (4): 375-90. 10.1093\/humupd\/dmi015.","journal-title":"Hum Reprod Update"},{"issue":"11","key":"9_CR167","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1093\/humrep\/deh440","volume":"19","author":"S Kashyap","year":"2004","unstructured":"Kashyap S, Wells GA, Rosenwaks Z: Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod. 2004, 19 (11): 2474-83. 10.1093\/humrep\/deh440.","journal-title":"Hum Reprod"},{"issue":"1","key":"9_CR168","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/humrep\/15.1.21","volume":"15","author":"A la Marca","year":"2000","unstructured":"la Marca A, Egbe TO, Morgante G: Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod. 2000, 15 (1): 21-3. 10.1093\/humrep\/15.1.21.","journal-title":"Hum Reprod"},{"issue":"1","key":"9_CR169","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejogrb.2004.09.015","volume":"121","author":"A La Marca","year":"2005","unstructured":"La Marca A, Artensio AC, Stabile G: Metformin treatment of PCOS during adolescence and the reproductive period. Eur J Obstet Gynecol Reprod Biol. 2005, 121 (1): 3-7. 10.1016\/j.ejogrb.2004.09.015.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"7421","key":"9_CR170","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bmj.327.7421.951","volume":"327","author":"JM Lord","year":"2003","unstructured":"Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003, 327 (7421): 951-3. 10.1136\/bmj.327.7421.951.","journal-title":"BMJ"},{"issue":"5","key":"9_CR171","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","volume":"43","author":"EM Velazquez","year":"1994","unstructured":"Velazquez EM, Mendoza S, Hamer T: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994, 43 (5): 647-54. 10.1016\/0026-0495(94)90209-7.","journal-title":"Metabolism"},{"issue":"6","key":"9_CR172","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMoa063971","volume":"356","author":"RS Legro","year":"2007","unstructured":"Legro RS, Barnhart HX, Schlaff WD: Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007, 356 (6): 551-66. 10.1056\/NEJMoa063971.","journal-title":"N Engl J Med"},{"issue":"12","key":"9_CR173","doi-asserted-by":"publisher","first-page":"E448","DOI":"10.1210\/jc.2010-0853","volume":"95","author":"E Vanky","year":"2010","unstructured":"Vanky E, Stridsklev S, Heimstad R: Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010, 95 (12): E448-55. 10.1210\/jc.2010-0853.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"9_CR174","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1093\/humrep\/dei072","volume":"20","author":"L Ibanez","year":"2005","unstructured":"Ibanez L, Jaramillo AM, Ferrer A: High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum Reprod. 2005, 20 (9): 2457-62. 10.1093\/humrep\/dei072.","journal-title":"Hum Reprod"},{"issue":"6","key":"9_CR175","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/jc.86.6.2453","volume":"86","author":"CC Kelly","year":"2001","unstructured":"Kelly CC, Lyall H, Petrie JR: Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001, 86 (6): 2453-5. 10.1210\/jc.86.6.2453.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"9_CR176","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1210\/jc.2002-021688","volume":"88","author":"L Morin-Papunen","year":"2003","unstructured":"Morin-Papunen L, Rautio K, Ruokonen A: Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003, 88 (10): 4649-54. 10.1210\/jc.2002-021688.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"9_CR177","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S1047-2797(03)00053-X","volume":"13","author":"KM Rexrode","year":"2003","unstructured":"Rexrode KM, Pradhan A, Manson JE: Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol. 2003, 13 (10): 674-82. 10.1016\/S1047-2797(03)00053-X.","journal-title":"Ann Epidemiol"},{"issue":"5","key":"9_CR178","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1210\/jc.2003-031096","volume":"89","author":"N Boulman","year":"2004","unstructured":"Boulman N, Levy Y, Leiba R: Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004, 89 (5): 2160-5. 10.1210\/jc.2003-031096.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR179","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1210\/jc.2004-0518","volume":"89","author":"BJ Goldstein","year":"2004","unstructured":"Goldstein BJ, Scalia R: Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004, 89 (6): 2563-8. 10.1210\/jc.2004-0518.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"9_CR180","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1210\/jc.2003-031867","volume":"89","author":"F Orio Jr","year":"2004","unstructured":"Orio F, Palomba S, Cascella T: Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004, 89 (9): 4588-93. 10.1210\/jc.2003-031867.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"9_CR181","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1210\/jc.2005-0965","volume":"90","author":"F Orio Jr","year":"2005","unstructured":"Orio F, Palomba S, Cascella T: Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab. 2005, 90 (11): 6072-6. 10.1210\/jc.2005-0965.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR182","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/jc.2004-0628","volume":"90","author":"F Orio Jr","year":"2005","unstructured":"Orio F, Palomba S, Cascella T: The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005, 90 (1): 2-5.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"9_CR183","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1210\/jc.2004-0751","volume":"89","author":"I Tarkun","year":"2004","unstructured":"Tarkun I, Arslan BC, Canturk Z: Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab. 2004, 89 (11): 5592-6. 10.1210\/jc.2004-0751.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"9_CR184","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1093\/humrep\/dei100","volume":"20","author":"B Vural","year":"2005","unstructured":"Vural B, Caliskan E, Turkoz E: Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod. 2005, 20 (9): 2409-13. 10.1093\/humrep\/dei100.","journal-title":"Hum Reprod"},{"issue":"10","key":"9_CR185","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1210\/jc.86.10.4666","volume":"86","author":"E Diamanti-Kandarakis","year":"2001","unstructured":"Diamanti-Kandarakis E, Spina G, Kouli C: Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab. 2001, 86 (10): 4666-73. 10.1210\/jc.86.10.4666.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9_CR186","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S0026-0495(97)90066-4","volume":"46","author":"EM Velazquez","year":"1997","unstructured":"Velazquez EM, Mendoza SG, Wang P: Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 1997, 46 (4): 454-7. 10.1016\/S0026-0495(97)90066-4.","journal-title":"Metabolism"},{"issue":"6","key":"9_CR187","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1093\/humrep\/del003","volume":"21","author":"E Diamanti-Kandarakis","year":"2006","unstructured":"Diamanti-Kandarakis E, Paterakis T, Alexandraki K: Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod. 2006, 21 (6): 1426-31. 10.1093\/humrep\/del003.","journal-title":"Hum Reprod"},{"issue":"5","key":"9_CR188","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1530\/eje.1.01910","volume":"152","author":"E Diamanti-Kandarakis","year":"2005","unstructured":"Diamanti-Kandarakis E, Alexandraki K, Protogerou A: Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005, 152 (5): 749-56. 10.1530\/eje.1.01910.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"9_CR189","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1210\/jc.2003-031281","volume":"89","author":"L Ibanez","year":"2004","unstructured":"Ibanez L, de Zegher F: Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab. 2004, 89 (4): 1592-7. 10.1210\/jc.2003-031281.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR190","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/humupd\/dmi054","volume":"12","author":"L Ibanez","year":"2006","unstructured":"Ibanez L, de Zegher F: Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update. 2006, 12 (3): 243-52. 10.1093\/humupd\/dmi054.","journal-title":"Hum Reprod Update"},{"issue":"4","key":"9_CR191","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.87.4.1555","volume":"87","author":"SA Arslanian","year":"2002","unstructured":"Arslanian SA, Lewy V, Danadian K: Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia\/insulin resistance. J Clin Endocrinol Metab. 2002, 87 (4): 1555-9. 10.1210\/jc.87.4.1555.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"9_CR192","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s001250051030","volume":"41","author":"L Ibanez","year":"1998","unstructured":"Ibanez L, Potau N, Chacon P: Hyperinsulinaemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche. Diabetologia. 1998, 41 (9): 1057-63. 10.1007\/s001250051030.","journal-title":"Diabetologia"},{"issue":"5","key":"9_CR193","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1515\/JPEM.2005.18.5.499","volume":"18","author":"I Guttmann-Bauman","year":"2005","unstructured":"Guttmann-Bauman I: Approach to adolescent polycystic ovary syndrome (PCOS) in the pediatric endocrine community in the U.S.A. J Pediatr Endocrinol Metab. 2005, 18 (5): 499-506. 10.1515\/JPEM.2005.18.5.499.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"8","key":"9_CR194","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1210\/jc.86.8.3595","volume":"86","author":"L Ibanez","year":"2001","unstructured":"Ibanez L, Valls C, Ferrer A: Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab. 2001, 86 (8): 3595-8. 10.1210\/jc.86.8.3595.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR195","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1210\/jc.2002-022002","volume":"88","author":"L Ibanez","year":"2003","unstructured":"Ibanez L, Ong K, Ferrer A: Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab. 2003, 88 (6): 2600-6. 10.1210\/jc.2002-022002.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"9_CR196","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1210\/jc.83.10.3558","volume":"83","author":"L Ibanez","year":"1998","unstructured":"Ibanez L, Potau N, Francois I: Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab. 1998, 83 (10): 3558-62. 10.1210\/jc.83.10.3558.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"9_CR197","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1210\/jc.85.10.3526","volume":"85","author":"L Ibanez","year":"2000","unstructured":"Ibanez L, Valls C, Potau N: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab. 2000, 85 (10): 3526-30. 10.1210\/jc.85.10.3526.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR198","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1530\/eje.0.1440619","volume":"144","author":"J Vrbikova","year":"2001","unstructured":"Vrbikova J, Hill M, Starka L: The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. Eur J Endocrinol. 2001, 144 (6): 619-28. 10.1530\/eje.0.1440619.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"9_CR199","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0015-0282(99)00407-0","volume":"72","author":"A la Marca","year":"1999","unstructured":"la Marca A, Morgante G, Paglia T: Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril. 1999, 72 (6): 985-9. 10.1016\/S0015-0282(99)00407-0.","journal-title":"Fertil Steril"},{"issue":"3","key":"9_CR200","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpedi.160.3.241","volume":"160","author":"T Bridger","year":"2006","unstructured":"Bridger T, MacDonald S, Baltzer F: Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2006, 160 (3): 241-6. 10.1001\/archpedi.160.3.241.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"3","key":"9_CR201","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1210\/jc.86.3.1430","volume":"86","author":"JE Nestler","year":"2001","unstructured":"Nestler JE: Metformin and the polycystic ovary syndrome. J Clin Endocrinol Metab. 2001, 86 (3): 1430-10.1210\/jc.86.3.1430.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9_CR202","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0026-0495(99)90113-0","volume":"48","author":"CJ Glueck","year":"1999","unstructured":"Glueck CJ, Wang P, Fontaine R: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism. 1999, 48 (4): 511-9. 10.1016\/S0026-0495(99)90113-0.","journal-title":"Metabolism"},{"issue":"2","key":"9_CR203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0015-0282(16)56518-2","volume":"61","author":"L Cusan","year":"1994","unstructured":"Cusan L, Dupont A, Gomez JL: Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril. 1994, 61 (2): 281-7.","journal-title":"Fertil Steril"},{"issue":"3","key":"9_CR204","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.0.1380269","volume":"138","author":"E Diamanti-Kandarakis","year":"1998","unstructured":"Diamanti-Kandarakis E, Kouli C, Tsianateli T: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998, 138 (3): 269-74. 10.1530\/eje.0.1380269.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9_CR205","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2265.2004.01973.x","volume":"60","author":"A Gambineri","year":"2004","unstructured":"Gambineri A, Pelusi C, Genghini S: Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004, 60 (2): 241-9. 10.1111\/j.1365-2265.2004.01973.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"9_CR206","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1210\/jc.87.6.2870","volume":"87","author":"L Ibanez","year":"2002","unstructured":"Ibanez L, Valls C, Ferrer A: Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab. 2002, 87 (6): 2870-4. 10.1210\/jc.87.6.2870.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR207","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1210\/jc.2003-031780","volume":"89","author":"MA Ganie","year":"2004","unstructured":"Ganie MA, Khurana ML, Eunice M: Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab. 2004, 89 (6): 2756-62. 10.1210\/jc.2003-031780.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9_CR208","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.1.01840","volume":"152","author":"K Rautio","year":"2005","unstructured":"Rautio K, Tapanainen JS, Ruokonen A: Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol. 2005, 152 (2): 269-75. 10.1530\/eje.1.01840.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9_CR209","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ejogrb.2004.06.035","volume":"118","author":"M Mitkov","year":"2005","unstructured":"Mitkov M, Pehlivanov B, Terzieva D: Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2005, 118 (2): 209-13. 10.1016\/j.ejogrb.2004.06.035.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"9_CR210","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1210\/jc.2002-020997","volume":"88","author":"L Morin-Papunen","year":"2003","unstructured":"Morin-Papunen L, Vauhkonen I, Koivunen R: Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2003, 88 (1): 148-56. 10.1210\/jc.2002-020997.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9_CR211","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejogrb.2005.05.010","volume":"123","author":"G Onalan","year":"2005","unstructured":"Onalan G, Goktolga U, Ceyhan T: Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. Eur J Obstet Gynecol Reprod Biol. 2005, 123 (2): 204-11. 10.1016\/j.ejogrb.2005.05.010.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"11","key":"9_CR212","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/BF03345339","volume":"28","author":"M Yilmaz","year":"2005","unstructured":"Yilmaz M, Biri A, Karakoc A: The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest. 2005, 28 (11): 1003-8.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"9_CR213","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1054-139X(01)00202-6","volume":"29","author":"CJ Glueck","year":"2001","unstructured":"Glueck CJ, Wang P, Fontaine R: Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health. 2001, 29 (3): 160-9. 10.1016\/S1054-139X(01)00202-6.","journal-title":"J Adolesc Health"},{"issue":"3","key":"9_CR214","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0029-7844(97)00296-2","volume":"90","author":"E Velazquez","year":"1997","unstructured":"Velazquez E, Acosta A, Mendoza SG: Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol. 1997, 90 (3): 392-5. 10.1016\/S0029-7844(97)00296-2.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"9_CR215","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0015-0282(98)00011-9","volume":"69","author":"LC Morin-Papunen","year":"1998","unstructured":"Morin-Papunen LC, Koivunen RM, Ruokonen A: Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998, 69 (4): 691-6. 10.1016\/S0015-0282(98)00011-9.","journal-title":"Fertil Steril"},{"issue":"9","key":"9_CR216","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1093\/humrep\/del185","volume":"21","author":"V De Leo","year":"2006","unstructured":"De Leo V, Musacchio MC, Morgante G: Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod. 2006, 21 (9): 2252-6. 10.1093\/humrep\/del185.","journal-title":"Hum Reprod"},{"issue":"6","key":"9_CR217","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1515\/JPEM.2006.19.6.831","volume":"19","author":"CJ Glueck","year":"2006","unstructured":"Glueck CJ, Aregawi D, Winiarska M: Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2006, 19 (6): 831-42. 10.1515\/JPEM.2006.19.6.831.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"9_CR218","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1210\/jc.2002-021528","volume":"88","author":"E Diamanti-Kandarakis","year":"2003","unstructured":"Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ: A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab. 2003, 88 (5): 1927-32. 10.1210\/jc.2002-021528.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR219","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/humupd\/dmi005","volume":"11","author":"J Vrbikova","year":"2005","unstructured":"Vrbikova J, Cibula D: Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update. 2005, 11 (3): 277-91. 10.1093\/humupd\/dmi005.","journal-title":"Hum Reprod Update"},{"issue":"8","key":"9_CR220","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1515\/JPEM.2005.18.8.761","volume":"18","author":"HF Allen","year":"2005","unstructured":"Allen HF, Mazzoni C, Heptulla RA: Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2005, 18 (8): 761-8. 10.1515\/JPEM.2005.18.8.761.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"8","key":"9_CR221","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/humrep\/deh329","volume":"19","author":"L Ibanez","year":"2004","unstructured":"Ibanez L, De Zegher F: Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Hum Reprod. 2004, 19 (8): 1725-7. 10.1093\/humrep\/deh329.","journal-title":"Hum Reprod"},{"issue":"1","key":"9_CR222","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/jc.2004-1405","volume":"90","author":"L Ibanez","year":"2005","unstructured":"Ibanez L, de Zegher F: Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab. 2005, 90 (1): 39-43.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"9_CR223","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1210\/jc.2004-0463","volume":"89","author":"L Ibanez","year":"2004","unstructured":"Ibanez L, Valls C, Marcos MV: Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. J Clin Endocrinol Metab. 2004, 89 (9): 4331-7. 10.1210\/jc.2004-0463.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"9_CR224","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/humrep\/17.7.1729","volume":"17","author":"K Elter","year":"2002","unstructured":"Elter K, Imir G, Durmusoglu F: Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod. 2002, 17 (7): 1729-37. 10.1093\/humrep\/17.7.1729.","journal-title":"Hum Reprod"},{"issue":"1","key":"9_CR225","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/humrep\/deh588","volume":"20","author":"D Cibula","year":"2005","unstructured":"Cibula D, Fanta M, Vrbikova J: The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod. 2005, 20 (1): 180-4.","journal-title":"Hum Reprod"},{"issue":"3","key":"9_CR226","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0303-7207(85)90059-0","volume":"42","author":"P Poyet","year":"1985","unstructured":"Poyet P, Labrie F: Comparison of the antiandrogenic\/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol. 1985, 42 (3): 283-8. 10.1016\/0303-7207(85)90059-0.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"9_CR227","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/09513590009167658","volume":"14","author":"II Muderris","year":"2000","unstructured":"Muderris II, Bayram F, Guven M: Treatment of hirsutism with lowest-dose flutamide (62.5 mg\/day). Gynecol Endocrinol. 2000, 14 (1): 38-41. 10.3109\/09513590009167658.","journal-title":"Gynecol Endocrinol"},{"issue":"7","key":"9_CR228","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1093\/humrep\/dei004","volume":"20","author":"L Ibanez","year":"2005","unstructured":"Ibanez L, Jaramillo A, Ferrer A: Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod. 2005, 20 (7): 1833-6. 10.1093\/humrep\/dei004.","journal-title":"Hum Reprod"},{"issue":"9","key":"9_CR229","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1210\/jc.85.9.3251","volume":"85","author":"L Ibanez","year":"2000","unstructured":"Ibanez L, Potau N, Marcos MV: Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab. 2000, 85 (9): 3251-5. 10.1210\/jc.85.9.3251.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"9_CR230","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1210\/jc.2002-020926","volume":"87","author":"L Ibanez","year":"2002","unstructured":"Ibanez L, Potau N, Ferrer A: Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab. 2002, 87 (12): 5702-5. 10.1210\/jc.2002-020926.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR231","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/humrep\/deg056","volume":"18","author":"L Ibanez","year":"2003","unstructured":"Ibanez L, de Zegher F: Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Hum Reprod. 2003, 18 (1): 57-60. 10.1093\/humrep\/deg056.","journal-title":"Hum Reprod"},{"issue":"9","key":"9_CR232","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1210\/jc.2004-0047","volume":"89","author":"L Ibanez","year":"2004","unstructured":"Ibanez L, Valls C, Cabre S: Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J Clin Endocrinol Metab. 2004, 89 (9): 4716-20. 10.1210\/jc.2004-0047.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"9_CR233","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1210\/jc.86.10.4618","volume":"86","author":"P Vuguin","year":"2001","unstructured":"Vuguin P, Saenger P, DiMartino-Nardi J: Fasting glucose insulin ratio: a useful measure of insulin resistance in girls with premature adrenarche. J Clin Endocrinol Metab. 2001, 86 (10): 4618-21. 10.1210\/jc.86.10.4618.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR234","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1210\/jc.86.6.2863","volume":"86","author":"ME Silfen","year":"2001","unstructured":"Silfen ME, Manibo AM, McMahon DJ: Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ratio may be a simple and useful measure. J Clin Endocrinol Metab. 2001, 86 (6): 2863-8. 10.1210\/jc.86.6.2863.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"9_CR235","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1210\/jc.83.8.2694","volume":"83","author":"RS Legro","year":"1998","unstructured":"Legro RS, Finegood DT, Dunaif A: A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998, 83 (8): 2694-8. 10.1210\/jc.83.8.2694.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9_CR236","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1046\/j.1365-2265.2001.01399.x","volume":"55","author":"L Ibanez","year":"2001","unstructured":"Ibanez L, Valls C, Potau N: Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endocrinol (Oxf). 2001, 55 (5): 667-72. 10.1046\/j.1365-2265.2001.01399.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"9_CR237","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jpeds.2003.08.015","volume":"144","author":"L Ibanez","year":"2004","unstructured":"Ibanez L, Ferrer A, Ong K: Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr. 2004, 144 (1): 23-9. 10.1016\/j.jpeds.2003.08.015.","journal-title":"J Pediatr"},{"issue":"4","key":"9_CR238","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.fertnstert.2004.02.127","volume":"82","author":"J Baillargeon","year":"2004","unstructured":"Baillargeon J, Jakubowicz DJ, Iuorno MJ: Effects of metformin and rosiglitazone, along and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004, 82 (4): 893-902. 10.1016\/j.fertnstert.2004.02.127.","journal-title":"Fertil Steril"},{"issue":"3","key":"9_CR239","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2004-1965","volume":"90","author":"C Ortega-Gonzalez","year":"2005","unstructured":"Ortega-Gonzalez C, Luna S, Hernandez L: Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005, 90 (3): 1360-5.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"9_CR240","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1210\/jc.82.7.2108","volume":"82","author":"DA Ehrmann","year":"1997","unstructured":"Ehrmann DA, Schneider DJ, Sobel BE: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997, 82 (7): 2108-16. 10.1210\/jc.82.7.2108.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9_CR241","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1530\/eje.1.01948","volume":"153","author":"I Tarkun","year":"2005","unstructured":"Tarkun I, Cetinarslan B, Turemen E: Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol. 2005, 153 (1): 115-21. 10.1530\/eje.1.01948.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"9_CR242","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1507\/endocrj.52.299","volume":"52","author":"D Dereli","year":"2005","unstructured":"Dereli D, Dereli T, Bayraktar F: Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J. 2005, 52 (3): 299-308. 10.1507\/endocrj.52.299.","journal-title":"Endocr J"},{"issue":"11","key":"9_CR243","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1210\/jc.2005-0469","volume":"90","author":"D Seto-Young","year":"2005","unstructured":"Seto-Young D, Paliou M, Schlosser J: Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab. 2005, 90 (11): 6099-105. 10.1210\/jc.2005-0469.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"9_CR244","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/humrep\/deg343","volume":"18","author":"CJ Glueck","year":"2003","unstructured":"Glueck CJ, Moreira A, Goldenberg N: Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod. 2003, 18 (8): 1618-25. 10.1093\/humrep\/deg343.","journal-title":"Hum Reprod"},{"issue":"9","key":"9_CR245","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1210\/jc.81.9.3299","volume":"81","author":"A Dunaif","year":"1996","unstructured":"Dunaif A, Scott D, Finegood D: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996, 81 (9): 3299-306. 10.1210\/jc.81.9.3299.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9_CR246","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0015-0282(98)00454-3","volume":"71","author":"I Hasegawa","year":"1999","unstructured":"Hasegawa I, Murakawa H, Suzuki M: Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril. 1999, 71 (2): 323-7. 10.1016\/S0015-0282(98)00454-3.","journal-title":"Fertil Steril"},{"issue":"3","key":"9_CR247","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1530\/EJE-08-0272","volume":"159","author":"A Gambineri","year":"2008","unstructured":"Gambineri A, Semple RK, Forlani G: Monogenic polycystic ovary syndrome due to a mutation in the lamin A\/C gene is sensitive to thiazolidinediones but not to metformin. Eur J Endocrinol. 2008, 159 (3): 347-53. 10.1530\/EJE-08-0272.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9_CR248","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2265.2010.03934.x","volume":"74","author":"S Franks","year":"2011","unstructured":"Franks S: When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?. Clin Endocrinol (Oxf). 2011, 74 (2): 148-51. 10.1111\/j.1365-2265.2010.03934.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"9_CR249","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1172\/JCI30558","volume":"117","author":"Y Shu","year":"2007","unstructured":"Shu Y, Sheardown SA, Brown C: Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007, 117 (5): 1422-31. 10.1172\/JCI30558.","journal-title":"J Clin Invest"},{"key":"9_CR250","volume-title":"Pharmacogenomics J","author":"G Ahlin","year":"2010","unstructured":"Ahlin G, Chen L, Lazorova L: Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J. 2010"},{"issue":"4","key":"9_CR251","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/tpj.2009.15","volume":"9","author":"ML Becker","year":"2009","unstructured":"Becker ML, Visser LE, van Schaik RH: Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009, 9 (4): 242-7. 10.1038\/tpj.2009.15.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"9_CR252","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/jhg.2008.1","volume":"54","author":"M Kajiwara","year":"2009","unstructured":"Kajiwara M, Terada T, Ogasawara K: Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. J Hum Genet. 2009, 54 (1): 40-6. 10.1038\/jhg.2008.1.","journal-title":"J Hum Genet"},{"issue":"2","key":"9_CR253","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1367\/A04-130R.1","volume":"5","author":"M Trent","year":"2005","unstructured":"Trent M, Austin SB, Rich M: Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr. 2005, 5 (2): 107-11. 10.1367\/A04-130R.1.","journal-title":"Ambul Pediatr"},{"issue":"6","key":"9_CR254","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1001\/archpedi.156.6.556","volume":"156","author":"ME Trent","year":"2002","unstructured":"Trent ME, Rich M, Austin SB: Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2002, 156 (6): 556-60.","journal-title":"Arch Pediatr Adolesc Med"}],"container-title":["International Journal of Pediatric Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1687-9856-2011-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1687-9856-2011-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1687-9856-2011-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:51:23Z","timestamp":1548118283000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijpeonline.biomedcentral.com\/articles\/10.1186\/1687-9856-2011-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,26]]},"references-count":254,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9"],"URL":"https:\/\/doi.org\/10.1186\/1687-9856-2011-9","relation":{},"ISSN":["1687-9856"],"issn-type":[{"value":"1687-9856","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,26]]},"article-number":"9"}}